Pharmacokinetics of tissue plasminogen activator in an isolated extracorporeal circuit

Journal of Vascular Surgery

Volumn 33, Issue 1, 2001, Pages 165-169

  Geier, Bruno ^a   Großefeld, Marcus ^a   Barbera, Letterio ^a   Mumme, Achim ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; EXTRACORPOREAL CIRCULATION; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; THROMBECTOMY;

EID: 0035140199     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.109765     Document Type: Article

References (27)

1. Modern day treatment of acute deep venous thrombosis
2. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry
3. A decision analysis of streptokinase plus heparin as compared with heparine alone for deep vein thrombosis
4. Thrombolytic therapy for acute deep vein thrombosis: How much is enough?
5. Thrombectomy, lysis or heparin treatment: Concurrent therapies of deep vein thrombosis: Therapy and experimental studies
6. Locoregional ultrahigh dosage fibrinolysis of deep leg vein thrombosis
7. Regional hyperthermic fibrinolytic perfusion in postoperative deep venous thrombosis of the leg
8. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit
9. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for limbs
10. Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent
11. Hyperthermic fibrinolysis with rt-PA: In vitro results
12. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction
13. Regional hyperthermic perfusion with fibrinolytic agents as the last resort in the critical ischemia of the lower extremities
14. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers
15. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis
16. Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism
17. Pharmacokinetics and fibrin specifity of alteplase during accelerated infusions in myocardial infarction
18. Catheter-directed thrombolysis of peripheral arterial occlusions and deep vein thrombosis
19. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease
20. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial graft occlusions: A randomized trial
21. Thrombolytic agents - An updated overview
22. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator
23. Differences in clot-lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)
24. Aprotinin: An antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo
25. Differential effects of aprotinin and tranexamic acid on cerebral bleeding and cutaneous bleeding time during rt-PA infusion
26. Inhibition of the fibrinolytic and fibrogenolytic activity of plasminogen activators in vitro by the antidotes aminocaproic acid, tranexamic acid and aprotinin
27. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)